COMPANY

Kiora Pharmaceuticals

HQ: Encinitas, CA source · kiorapharma.com ↗ · West Coast

Keywords: small molecule ophthalmology retinal disease Retinitis Pigmentosa Macular Edema Choroideremia Non-Syndromic Rod-Dominant Inherited Retinal Diseases Persistent Corneal Epithelial Defect Dry Eye Disease KIO-104 KIO-301 KIO-101

Location: Encinitas, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

$5.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

Aug 19, 2026 Partnership Partnership / licensing: $1M (upfront, as published), announced Aug 19, 2026. Source: SEC filing. source ↗
Apr 7, 2026 Raise Private placement: $5M (initial closing, as published); deal value up to $24M (not counted as received), announced Apr 7, 2026. Source: SEC filing. source ↗ · Form D filed Apr 21, 2026 SEC Form D ↗
Aug 29, 2025 Trial start II: A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa source ↗
May 1, 2025 Trial start Phase 2: Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema source ↗
Mar 15, 2023 Trial start 2: A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With A source ↗
Nov 10, 2022 Trial start I: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) source ↗
Jul 1, 2022 Trial start Phase 2: A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 2 · Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema · NCT06825702
2027-08 (ESTIMATED) · II · A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa · NCT06628947

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $5.0M. Last 2 years.

Apr 7, 2026 Private placement: $5M (initial closing, as published); deal value up to $24M (not counted as received), announced Apr 7, 2026. Source: SEC filing. source ↗ · Form D filed Apr 21, 2026 SEC Form D ↗
Aug 19, 2026 Partnership / licensing: $1M (upfront, as published), announced Aug 19, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06825702	Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema	Phase 2	Recruiting	May 1, 2025	2026-11 (estimated)
NCT06628947	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa	II	Recruiting	Aug 29, 2025	2027-08 (estimated)
NCT05282953	A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)	I	Completed	Nov 10, 2022	Aug 10, 2023 (actual)
NCT05436288	A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects	Phase 2	Completed	Jul 1, 2022	Dec 22, 2022 (actual)
NCT05629364	A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease	2	Terminated	Mar 15, 2023	Jan 9, 2024 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-04-21 Raise Private raise (SEC Form D): $5.0M sold; issuer “KIORA PHARMACEUTICALS INC”. Verified from the SEC filing. SEC filing ↗